Covidien’s Mallinckrodt Inc. unit based in Hazelwood has acquired the licensing rights to Exalgo, an extended release formulation of hydromorphone, from a unit of Neuromed Pharmaceuticals Ltd.

Exalgo, an opioid analgesic, is awaiting Food and Drug Administration approval. Financial terms of the deal…

Covidien Ltd., which has 3,000 area employees in two Hazelwood-based business units operating as Mallinckrodt Inc., on Thursday reported a 9 percent gain in first-quarter net sales, to $2.3 billion from $2.1 billion a year ago. Higher volume sales and…

Federal regulators are inspecting the Hazelwood-based Mallinckrodt unit of Covidien Inc. after learning of problems with generators it sold for use in nuclear medicine.

The Nuclear Regulatory Commission said Wednesday that the generators were producing doses containing a nuclear isotope, molybdenum-99, that should…